Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain

<p>Abstract</p> <p>Background</p> <p>This study was conducted in order to determine the use of aspirin and to assess the achievement of therapeutic targets in diabetic patients according to primary (PP) or secondary prevention (SP).</p> <p>Methods</p>...

Full description

Bibliographic Details
Main Authors: Fernández-de-Bobadilla Jaime, Rejas-Gutiérrez Javier, Navarro-Artieda Ruth, Sicras-Mainar Antoni, Frías-Garrido Xavier, Ruiz-Riera Rafael
Format: Article
Language:English
Published: BMC 2007-10-01
Series:BMC Family Practice
Online Access:http://www.biomedcentral.com/1471-2296/8/60
id doaj-938d85936faa41269036bc7c9f1b7469
record_format Article
spelling doaj-938d85936faa41269036bc7c9f1b74692020-11-25T03:55:12ZengBMCBMC Family Practice1471-22962007-10-01816010.1186/1471-2296-8-60Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in SpainFernández-de-Bobadilla JaimeRejas-Gutiérrez JavierNavarro-Artieda RuthSicras-Mainar AntoniFrías-Garrido XavierRuiz-Riera Rafael<p>Abstract</p> <p>Background</p> <p>This study was conducted in order to determine the use of aspirin and to assess the achievement of therapeutic targets in diabetic patients according to primary (PP) or secondary prevention (SP).</p> <p>Methods</p> <p>This is a retrospective, observational study including patients ≥18 years with diabetes mellitus followed in four primary care centers. Measurements included demographics, use of aspirin and/or anticoagulant drugs, co-morbidities, clinical parameters and proportion of patient at therapeutic target (TT). Descriptive statistics, chi-square test and logistic regression model were used for significance.</p> <p>Results</p> <p>A total of 4,140 patients were analyzed, 79.1% (95% confidence intervals [CI]: 77.7–80.5%) in PP and 20.9% (95% CI: 18.2–23.7%) in SP. Mean age was 64.1 (13.8) years, and 49.3% of patient were men (PP: 46.3, SP: 60.7, p = 0.001). Aspirin was prescribed routinely in 20.8% (95% CI: 19.4–22.2%) in PP and 60.8% (95% CI: 57.6–64.0%) in SP. Proportion of patient at TT was 48.0% for blood pressure and 59.8% for cholesterol. Use of aspirin was associated to increased age [OR = 1.01 (95% CI: 1.00–1.02); p = 0.011], cardiovascular-risk factors [OR = 1.14 (95% CI: 1.03–1.27); p = 0.013], LDL-C [OR = 1.42 (95% CI: 1.06–1.88); p = 0.017] and higher glycated hemoglobin [OR = 1.51 (95% CI: 1.22–1.89); p = 0.000] were covariates associated to the use of aspirin in PP.</p> <p>Conclusion</p> <p>Treatment with aspirin is underused for PP in patients with diabetes mellitus in Primary Care. Achievement of TT should be improved.</p> http://www.biomedcentral.com/1471-2296/8/60
collection DOAJ
language English
format Article
sources DOAJ
author Fernández-de-Bobadilla Jaime
Rejas-Gutiérrez Javier
Navarro-Artieda Ruth
Sicras-Mainar Antoni
Frías-Garrido Xavier
Ruiz-Riera Rafael
spellingShingle Fernández-de-Bobadilla Jaime
Rejas-Gutiérrez Javier
Navarro-Artieda Ruth
Sicras-Mainar Antoni
Frías-Garrido Xavier
Ruiz-Riera Rafael
Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
BMC Family Practice
author_facet Fernández-de-Bobadilla Jaime
Rejas-Gutiérrez Javier
Navarro-Artieda Ruth
Sicras-Mainar Antoni
Frías-Garrido Xavier
Ruiz-Riera Rafael
author_sort Fernández-de-Bobadilla Jaime
title Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
title_short Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
title_full Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
title_fullStr Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
title_full_unstemmed Use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in Spain
title_sort use of aspirin for primary and secondary prevention of cardiovascular disease in diabetic patients in an ambulatory care setting in spain
publisher BMC
series BMC Family Practice
issn 1471-2296
publishDate 2007-10-01
description <p>Abstract</p> <p>Background</p> <p>This study was conducted in order to determine the use of aspirin and to assess the achievement of therapeutic targets in diabetic patients according to primary (PP) or secondary prevention (SP).</p> <p>Methods</p> <p>This is a retrospective, observational study including patients ≥18 years with diabetes mellitus followed in four primary care centers. Measurements included demographics, use of aspirin and/or anticoagulant drugs, co-morbidities, clinical parameters and proportion of patient at therapeutic target (TT). Descriptive statistics, chi-square test and logistic regression model were used for significance.</p> <p>Results</p> <p>A total of 4,140 patients were analyzed, 79.1% (95% confidence intervals [CI]: 77.7–80.5%) in PP and 20.9% (95% CI: 18.2–23.7%) in SP. Mean age was 64.1 (13.8) years, and 49.3% of patient were men (PP: 46.3, SP: 60.7, p = 0.001). Aspirin was prescribed routinely in 20.8% (95% CI: 19.4–22.2%) in PP and 60.8% (95% CI: 57.6–64.0%) in SP. Proportion of patient at TT was 48.0% for blood pressure and 59.8% for cholesterol. Use of aspirin was associated to increased age [OR = 1.01 (95% CI: 1.00–1.02); p = 0.011], cardiovascular-risk factors [OR = 1.14 (95% CI: 1.03–1.27); p = 0.013], LDL-C [OR = 1.42 (95% CI: 1.06–1.88); p = 0.017] and higher glycated hemoglobin [OR = 1.51 (95% CI: 1.22–1.89); p = 0.000] were covariates associated to the use of aspirin in PP.</p> <p>Conclusion</p> <p>Treatment with aspirin is underused for PP in patients with diabetes mellitus in Primary Care. Achievement of TT should be improved.</p>
url http://www.biomedcentral.com/1471-2296/8/60
work_keys_str_mv AT fernandezdebobadillajaime useofaspirinforprimaryandsecondarypreventionofcardiovasculardiseaseindiabeticpatientsinanambulatorycaresettinginspain
AT rejasgutierrezjavier useofaspirinforprimaryandsecondarypreventionofcardiovasculardiseaseindiabeticpatientsinanambulatorycaresettinginspain
AT navarroartiedaruth useofaspirinforprimaryandsecondarypreventionofcardiovasculardiseaseindiabeticpatientsinanambulatorycaresettinginspain
AT sicrasmainarantoni useofaspirinforprimaryandsecondarypreventionofcardiovasculardiseaseindiabeticpatientsinanambulatorycaresettinginspain
AT friasgarridoxavier useofaspirinforprimaryandsecondarypreventionofcardiovasculardiseaseindiabeticpatientsinanambulatorycaresettinginspain
AT ruizrierarafael useofaspirinforprimaryandsecondarypreventionofcardiovasculardiseaseindiabeticpatientsinanambulatorycaresettinginspain
_version_ 1724470047087263744